Added to YB: 2026-09-14
Pitch date: 2026-09-10
FDMT [neutral]
4D Molecular Therapeutics, Inc.
Author Info
No bio for this author
Company Info
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
Market Cap
$783.4M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.17
P/E
-5.11
EV/Sales
4.26
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 3 session 1 - 4D Molecular Therapeutics, Inc.
FDMT (quick overview): 4D Molecular Therapeutics’ 4D-150 offers a clear clinical-to-commercial proposition: preserve vision in wet AMD while sharply reducing repeated anti-VEGF injections. Phase 2 PRISM showed maintained visual acuity, continued anatomic control, roughly 78% lower treatment burden overall and a durable effect through two years, with no new intraocular inflammation signals in reported follow-up. The thesis hinges on reproducing that benefit in randomized Phase 3 trials and securing favorable reimbursement; success could make 4D-150 a category-defining retinal gene therapy.
Read full article (2 min)